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Jens K Møller,6 Casper Roed,1 Lars H Omland,1 Claus B Christiansen,7 Svend Ellermann-Eriksen,8 
Jette M Bangsborg,9 Klaus Hansen,10 Thomas L Benfield,11 Kenneth J Rothman,12,13  
Henrik T Sørensen,12 Christian Ø Andersen,14 Anne-Mette Lebech1
ABSTRACT
OBJECTIVE
To estimate long term survival, health, and 
educational/social functioning in patients with 
Lyme neuroborreliosis compared with the general 
population.
DESIGN
Nationwide population based cohort study using 
national registers.
SETTING
Denmark.
PARTICIPANTS
All Danish residents diagnosed during 1986-2016 as 
having Lyme neuroborreliosis (n=2067), defined as 
a positive Borrelia burgdorferi intrathecal antibody 
test and a clinical diagnosis of Lyme borreliosis, and 
a comparison cohort from the general population 
matched on sex and date of birth (n=20 670).
MAIN OUTCOME MEASURES
Mortality rate ratios, incidence rate ratios of 
comorbidities, and differences in educational and 
social outcomes.
RESULTS
Mortality among patients with Lyme neuroborreliosis 
was not higher than in the general population 
(mortality rate ratio 0.90, 95% confidence interval 
0.79 to 1.03). Lyme neuroborreliosis patients 
had increased risk of haematological (incidence 
rate ratio 3.07, 2.03 to 4.66) and non-melanoma 
skin cancers (1.49, 1.18 to 1.88). At diagnosis, 
Lyme neuroborreliosis patients had slightly higher 
employment and lower disability pension rates. 
After five years, patients and comparison cohort 
members had similar numbers of hospital contacts 
(difference −0.22, 95% confidence interval −0.45 
to 0.02, in-hospital days/year; 0.37, −0.10 to 
0.83, outpatient visits/year), employment rates 
(difference 1.5%, −2.1% to 5.1%), income (difference 
−1000, −20 000 to 18 000, Danish kroner), days of 
sick leave (difference −0.3, −3.5 to 3.0, per year), 
rates of receipt of a disability pension (difference 
−0.9%, −3.2% to 1.3%), and number of children 
(difference –0.10, −0.27 to 0.08). More patients were 
married (difference 4.8%, 2.2% to 7.4%) and had 
completed high school education (difference 7%, 
1% to 12%).
CONCLUSION
A verified diagnosis of Lyme neuroborreliosis 
had no substantial effect on long term survival, 
health, or educational/social functioning. 
Nevertheless, the diagnosis decreased labour market 
involvement marginally and was associated with 
increased risk of haematological and non-melanoma 
skin cancers.
Introduction
Lyme neuroborreliosis is a tickborne infection caused 
by the spirochetes of the Borrelia burgdorferi sensu lato 
complex (including B garinii and B afzelii in Europe). 
In Europe, Lyme neuroborreliosis is among the most 
frequent bacterial infections of the nervous system and 
mainly manifests as a self limiting, subacute, painful 
meningoradiculitis with concomitant lymphocytic 
cerebrospinal fluid inflammation.1-6 In children, 
Lyme neuroborreliosis primarily leads to subacute 
lymphocytic meningitis.7
Antibiotic treatment improves neurological 
symptoms. However, studies on the long term 
outcome of Lyme neuroborreliosis are scarce and 
hampered by small study populations, short term 
follow-up, and lack of adequate comparison cohorts.3 
8-13 A systematic review of 44 clinical trials reported 
a 28% prevalence of residual symptoms after Lyme 
neuroborreliosis, including fatigue, pain, and 
neurological or cognitive sequelae. Few of the studies 
included control cohorts.14 Improved information 
on long term prognosis after an episode of Lyme 
neuroborreliosis is needed by patients, medical staff, 
and healthcare providers.
We used a nationwide population based matched 
cohort design to compare long term survival, health, 
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WhAT IS AlReAdy knoWn on ThIS TopIC
In Europe, Lyme neuroborreliosis is among the most frequent bacterial infections 
of the nervous system, but the long term prognosis of the disease is poorly 
described
WhAT ThIS STudy AddS
Lyme neuroborreliosis had no substantial effect on survival, health, and social 
parameters
Compared with members of the comparison cohort, patients had a threefold 
higher risk of haematological cancer, almost 50% higher risk of non-melanoma 
skin cancer, and a slightly higher risk of disability pension
Lyme neuroborreliosis patients have increased risk of haematological and 
non-melanoma skin cancers but can otherwise be assured that their long term 
prognosis is excellent
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social functioning, and education among patients with 
Lyme neuroborreliosis and a comparison cohort from 
the general population. To establish whether potential 
differences stemmed from family related factors, we 
also compared the same outcomes among family 
members of the patient and comparison cohorts.
Methods
Setting
Denmark’s population on 31 December 2017 was 5.7 
million people. Tax supported healthcare is provided 
free of charge to all Danish residents. Almost 5000 
intrathecal antibody tests for B burgdorferi are 
performed yearly in Denmark.2
Data sources
We used a population based nationwide cohort design, 
as described previously.15 We used the unique 10 digit 
personal identification number assigned to all Danish 
residents at birth or on immigration to track individuals 
in Danish national health and administrative registries. 
Data on B burgdorferi intrathecal antibody tests came 
from data files obtained from all Danish microbiology 
laboratories that performed this test during the period 
1 January 1985 to 1 March 2016. B burgdorferi specific 
intrathecal antibody production was measured by 
capture enzyme linked immunosorbent assays (see 
supplementary appendix).16 Additional data came 
from the Danish Civil Registration System, the Danish 
National Patient Registry (DNPR), the Danish Cancer 
Registry, the Employment Classification Module, the 
Personal Income Statistics database, and the Danish 
Educational Attainment Registry (see supplementary 
appendix).
Study population
Lyme neuroborreliosis patient cohort
We identified the Lyme neuroborreliosis patient 
cohort through collaboration with all microbiology 
laboratories in Denmark. Using electronic and paper 
laboratory files, we identified all people who had a B 
burgdorferi intrathecal antibody test performed during 
the period 1 January 1985 to 1 March 2016. From this 
population, we extracted all patients with a positive B 
burgdorferi intrathecal IgG and/or IgM test who were 
Danish residents at study inclusion (supplementary 
figure A). We defined the first date of a positive B 
burgdorferi intrathecal antibody test as the date of 
study inclusion. We excluded patients from the study if 
they were not registered with a diagnosis of borreliosis 
in the DNPR within one year after study inclusion or 
had a contact with a department of neurology earlier 
than one year before study inclusion.
Population comparison cohort
For each Lyme neuroborreliosis patient, we used the 
Danish Civil Registration System and the DNPR to 
identify all Danish residents with the same sex and 
date of birth as the patient who had not tested positive 
for B burgdorferi intrathecal antibodies and who met 
the study’s inclusion and exclusion criteria (other 
than a diagnosis of borreliosis) described above for 
the patient cohort. From this population, we extracted 
10 people at random for each patient. People in the 
population comparison cohort were assigned the same 
date of study inclusion as the Lyme neuroborreliosis 
patients to whom they were matched.
Family member cohorts
A diagnosis of Lyme neuroborreliosis may be related to 
healthcare seeking behaviour and outdoor recreational 
activities and thereby to higher socioeconomic status. 
To assess the magnitude of this effect, we used the 
Danish Civil Registration System to identify siblings 
and parents of the Lyme neuroborreliosis patients 
and of members of the population comparison cohort. 
Family members were assigned the same date of study 
inclusion as their relatives in the Lyme neuroborreliosis 
patient cohort or population comparison cohort 
(supplementary figure A). As registration of parents 
is complete only for people born after 1957, family 
members could not be identified for all study 
participants.
Statistical analysis
We ascertained time to death, diagnoses of cancers, 
and potential medical sequelae (supplementary 
appendix). We calculated time from date of study 
inclusion to 1 March 2016, death, emigration, loss to 
follow-up, or event of interest, whichever came first. 
We calculated mortality rate ratios and incidence 
rate ratios as measures of relative risk. We included 
patients registered with a diagnosis of borreliosis in 
the DNPR up to one year after study inclusion. As this 
may introduce immortal time bias, we did a sensitivity 
analyses in which we calculated time from the later of 
study inclusion and registration in the DNPR.
For each person in the patient and comparison 
cohorts, we ascertained the number of hospital 
inpatient days and outpatient hospital visits, 
employment status, personal income, number of days 
of sick leave, receipt of a disability pension, marital 
status, and number of children for each year starting 
10 years before the date of study inclusion, birth, 
immigration, or start-up date of the registry recording 
the outcome of interest, up until the earliest of the 
following events: 10 years after study inclusion, 1 
March 2016, death, emigration, or loss to follow-up. 
We calculated differences in each outcome between the 
patient and comparison cohorts, with 95% confidence 
intervals. For children, we ascertained the grade 
received in written mathematics during the last year 
of primary school. We calculated time from age 17 to 
high school graduation and used Kaplan-Meier tables 
to calculate cumulative incidences of high school 
graduation at age 25. Analyses of income, sick leave, 
receipt of a disability pension, and number of children 
were restricted to people aged 20-60 years at study 
inclusion. Analyses of sick leave included only people 
registered as employed. To account for potential 
differences in comorbidity at time of study inclusion, 
we calculated the fraction of people with a Charlson 
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Comorbidity Index score greater than 0 at study 
inclusion.17 18 We did similar calculations comparing 
family members of Lyme neuroborreliosis patients 
with family members of people in the population 
comparison cohort. We used SPSS Statistics version 24 
and STATA version 14 for the analyses.
Patient involvement
No patients were involved in setting the research 
question or the outcome measures, nor were 
they involved in developing plans for design or 
implementation of the study. No patients were asked to 
advise on interpretation or writing up of results. There 
are no plans to disseminate the results of the research 
to study participants or the relevant patient community.
Results
During the study period, we identified 3200 people 
with a positive B burgdorferi intrathecal test 
(supplementary figure A). Of these, 1047 (33%) did not 
have a diagnosis of borreliosis recorded in the DNPR 
and 86 (3%) were registered as having had contact with 
a department of neurology more than one year before 
study inclusion. After these exclusions, 2067 patients 
and 20 670 members of the population comparison 
cohort remained in the study. Patients and members of 
the comparison cohort were well matched with respect 
to Charlson Comorbidity Index score and risk of cancer 
before study inclusion (table  1). We identified 3793 
family members of people in the patient cohort and 
37 579 family members of people in the population 
comparison cohort (table 1).
A total of 247 (12%) Lyme neuroborreliosis patients 
and 2728 (13%) people in the population comparison 
cohort died during the observation period (table 1). 
Mortality was not higher among patients in the Lyme 
neuroborreliosis cohort (mortality rate ratio 0.90, 
95% confidence interval 0.79 to 1.03) or their family 
members (0.93, 0.81 to 1.07) compared with people 
in the population comparison cohort and their family 
members (table 2, fig 1, supplementary figure B). Fifty 
nine patients were registered as having borreliosis in 
the DNPR more than one month after study inclusion, 
which may have introduced immortal time bias. 
The mortality estimate was not changed when we 
calculated time starting from study inclusion versus 
date of registration in the DNPR, whichever was later 
(mortality rate ratio 0.90, 0.79 to 1.03).
The risk of a new cancer was higher in the Lyme 
neuroborreliosis cohort than in the population 
comparison cohort (table 2). The increased risk stemmed 
mainly from a threefold higher risk of haematological 
cancer among Lyme neuroborreliosis patients; 29 
patients and 94 comparison cohort members were 
diagnosed as having haematological cancer (table  2, 
fig 2). The Lyme neuroborreliosis population had 
increased risks of lymphoma, myelomatosis, and 
chronic lymphatic leukaemia (table 2). Mortality after 
a diagnosis of haematological cancer did not differ 
substantially between the patients and the population 
comparison cohort (mortality rate ratio 1.05, 0.65 to 
1.69) (supplementary figure C). The increased risk of 
haematological cancer was evident throughout the 
study period and was also observed in a sensitivity 
analysis excluding patients who had a contact with a 
department of haematology before and up to one year 
after study inclusion (incidence rate ratio 2.84, 95% 
confidence interval 1.81 to 4.47). In addition, the 
risk of non-melanoma skin cancers was almost 50% 
higher in the patient cohort than in the population 
comparison cohort. Risks of haematological cancers 
and non-melanoma skin cancers were not increased 
among family members of Lyme neuroborreliosis 
patients (table 2, supplementary figure B).
Table 1 | Characteristics of patients diagnosed as having Lyme neuroborreliosis (LNB), members of population comparison cohort, and family 
members of people in these two cohorts, Denmark, 1985-2016. Values are numbers (percentages) unless stated otherwise
Characteristics
LNB patients  
(n=2067)
Population comparison  
cohort (n=20 670)
Family members of LNB  
patients (n=3793)
Family members of population  
comparison cohort (n=37 579)
Female sex 1160 (56) 11 600 (56) 1881 (50) 18 900 (50)
Median (interquartile range) age at study inclusion, years 45 (11-62) 45 (11-62) 37 (17-47) 37 (18-47)
Age <16 years at study inclusion 644 (31) 6440 (31) 2264 (60) 22 458 (60)
Born in Denmark 2012 (97) 19 385 (94) 3739 (99) 36 045 (96)
Charlson Comorbidity Index score >0*† 272 (13) 3135 (15) 426 (11) 4199 (11)
Cancer, total† 99 (4.8) 910 (4.4) 67 (1.8) 818 (2.2)
Non-melanoma-skin cancer† 37 (1.8) 318 (1.5) 4 (0.1) 93 (0.2)
Haematological cancer† 10 (0.5) 36 (0.2) 1 (0.03) 36 (0.1)
Other cancers† 52 (2.5) 556 (2.7) 62 (1.6) 689 (1.8)
Fathers – – 920 (24) 8822 (24)
Mothers – – 999 (26) 9662 (26)
Siblings – – 1874 (49) 19 095 (51)
Median (interquartile range) observation time, years 11.4 (6.1-16.3) 11.4 (6.3-16.2) 11.6 (6.3-16.5) 11.6 (6.4-16.5)
Total observation time, years 23 551 233 740 44 100 432 625
Died‡ 247 (12) 2728 (13) 215 (5.7) 2278 (6.1)
Emigrated‡ 74 (3.6) 340 (1.6) 36 (0.9) 601 (1.6)
Lost to follow-up‡ 0 11 (0.05) 0 16 (0.04)
*Modified Charlson Comorbidity Index (CCI) score derived from diagnoses recorded in Danish National Patient Registry at study inclusion. CCI assigns a score to a range of comorbidities known 
to be predictive of mortality. For simplicity, scores are dichotomised (CCI score=0 and CCI score>0).
†Diagnosed before study inclusion.
‡During follow-up.
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We observed no increased risk of multiple sclerosis, 
skin diseases, heart block, or cardiac arrest in the Lyme 
neuroborreliosis patients (table 2, supplementary 
figure C). Risks of arthritis and cerebral infarction were 
increased among Lyme neuroborreliosis patients only 
during the first year after study inclusion (table 2).
Days of hospital admission and use of outpatient 
services were considerably higher in the patient cohort 
than in the general population comparison cohort 
during the year of Lyme neuroborreliosis diagnosis and 
then attenuated. Use of outpatient services remained 
slightly increased among Lyme neuroborreliosis 
patients for several years after diagnosis, particularly 
for services in haematology and neurology clinics 
(table 3, supplementary figure C). We observed no 
increased use of inpatient or outpatient hospital 
services in the family member cohort during the study 
period (table 3, supplementary figure D).
The employment rate for people in the Lyme 
neuroborreliosis cohort was higher than in the 
population comparison cohort, although the rate in the 
patient cohort decreased slightly after study inclusion 
(table 3, supplementary figure E). Before study 
inclusion, the rate of receipt of disability pensions 
was lower among Lyme neuroborreliosis patients than 
among members of the population comparison cohort 
(table 3). Although the rate of receipt of disability 
pensions among patients increased after the date 
of study inclusion, it did not exceed the rate in the 
population comparison cohort (table 3, fig 3 (top)). We 
also observed a higher employment rate and a lower 
rate of receipt of disability pension among family 
members of Lyme neuroborreliosis patients, compared 
with family members of people in the general 
population comparison cohort (table 3, fig 3 (bottom), 
supplementary figure E).
Table 2 | Mortality rate ratios and incidence rate ratios for specific diagnoses in Lyme neuroborreliosis (LNB) 
patients and their families, compared with members of matched general population cohort and their families, 
Denmark 1985-2016.
LNB patients v population  
comparison cohort members
Family members of LNB patients v family 
 members of population comparison cohort
Mortality 0.90 (0.79 to 1.03) 0.93 (0.81 to 1.07)
Cancer 1.32 (1.15 to 1.52) 1.06 (0.92 to 1.22)
Non-haematological cancer 1.19 (1.00 to 1.14) 1.12 (0.94 to 1.32)
Haematological cancer 3.07 (2.03 to 4.66) 0.25 (0.08 to 0.77)
 Lymphoma 4.10 (2.20 to 7.64) –
 Myelomatosis 2.62 (0.98 to 7.019) –
 Leukaemia (not chronic lymphatic leukaemia) 1.36 (0.41 to 4.54) –
 Chronic lymphatic leukaemia 3.67 (1.54 to 8.72) –
Non-melanoma skin cancer 1.49 (1.18 to 1.88) 1.11 (0.94 to 1.32)
Multiple sclerosis 1.24 (0.37 to 4.12) 1.14 (0.52 to 2.49)
Arthritis <1 year after study inclusion* 9.04 (3.67 to 22.24) 1.30 (0.80 to 2.10)
Arthritis ≥1 year after study inclusion 1.58 (0.88 to 2.84) –
Skin diseases 0.88 (0.41 to 1.91) 0.67 (0.37 to 1.21)
Cerebral infarction <1 year after study inclusion* 4.85 (2.92 to 8.05) 0.99 (0.77 to 1.28)
Cerebral infarction ≥1 year after study inclusion 1.18 (0.93 to 1.50) –
Heart block or cardiac arrest 1.00 (0.54 to 1.87) 0.98 (0.53 to 1.83)
*Data for family members of LNB patients versus family members of people in population comparison cohort cover whole study period.
Years aer study inclusion
Pr
ob
ab
ili
ty
 o
f s
ur
vi
va
l (
%
)
No at risk
0 5 10 15 20 25 30
2067
20 670
1653
16 336
1198
11 830
624
6180
174
1821
44
425
6
56
0
20
40
60
80
100
LNB patients
LNB patients
Comparison cohort
Comparison cohort
Fig 1 | Cumulative survival of 2067 Lyme neuroborreliosis 
(LNB) patients and 20 670 members of population 
comparison cohort
Years aer study inclusion
Cu
m
ul
at
iv
e 
in
ci
de
nc
e 
of
ha
em
at
ol
og
ic
al
 ca
ne
r (
%
)
No at risk
0 5 10 15 20
2057
20 634
1642
16 295
1190
11 798
619
6158
173
1814
0
0.5
1.0
1.5
2.0
2.5
LNB patients
LNB patients
Comparison cohort
Comparison cohort
Fig 2 | Cumulative incidence of haematological cancer 
among Lyme neuroborreliosis (LNB) patients and 
members of population comparison cohort
 o
n
 13 June 2019 by guest. Protected by copyright.
http://www.bmj.com/
BM
J: first published as 10.1136/bmj.k1998 on 30 May 2018. Downloaded from 
RESEARCH
the bmj | BMJ 2018;361:k1998 | doi: 10.1136/bmj.k1998 5
Table 3 | Hospital inpatient days, number of outpatient visits, employment status, personal income, sick leave, proportion receiving disability pension, 
marital status, number of children, elementary school grades in written mathematics, and cumulative incidence of graduation from high school among 
patients with Lyme neuroborreliosis (LNB), members of population comparison cohort, and family members of these two cohorts, Denmark 1985-2016
Years from study inclusion LNB patients
Population  
comparison  
cohort Difference (95%CI)
Family members  
of LNB patients
Family members  
of population  
comparison cohort Difference (95%CI)
Hospital admission (mean inpatient days/year)
−2 0.71 0.54 0.17 (−0.31 to 0.66) 0.61 0.69 −0.09 (−0.23 to 0.06)
0 14.21 0.76 13.45 (12.78 to 14.12) 0.88 0.80 0.07 (−0.12 to 0.27)
1 0.98 0.95 0.03 (−0.22 to 0.29) 0.95 0.82 0.13 (−0.11 to 0.36)
5 0.68 0.90 −0.22 (−0.45 to 0.02) 0.99 0.81 0.17 (−0.23 to 0.57)
10 1.31 0.95 0.36 (−0.17 to 0.89) 0.87 0.82 0.06 (−0.25 to 0.37)
Outpatient visits (mean visits/year)
−2 0.80 0.87 −0.08 (−0.25 to 0.10) 0.81 0.85 −0.04 (−0.12 to 0.05)
0 4.61 1.07 3.54 (3.13 to 3.95) 1.02 0.98 0.04 (−0.08 to 0.15)
1 1.72 1.12 0.60 (0.03 to 0.90) 1.10 1.03 0.07 (−0.05 to 0.19)
5 1.72 1.35 0.37 (−0.10 to 0.83) 1.17 1.20 −0.03 (−0.15 to 0.10)
10 1.71 1.64 0.07 (−0.40 to 0.54) 1.58 1.51 0.07 (−0.13 to 0.27)
Proportion employed (%)*
−2 90 86 3.9 (1.7 to 6.1) 91 88 2.7 (1.4 to 4.0)
0 86 82 3.6 (1.1 to 6.2) 86 83 2.9 (1.4 to 4.4)
1 81 80 0.8 (−2.1 to 3.6) 84 80 3.7 (2.1 to 0.3)
5 70 69 1.5 (−2.1 to 5.1) 79 76 3.7 (1.8 to 5.7)
10 51 51 0.3 (−4.8 to 4.3) 65 63 2.3 (−0.3 to 4.9)
Mean yearly income (Danish Kroner, thousands)*
−2 262 245 17 (6 to 28) 277 261 16 (7 to 25)
0 250 248 2 (−10 to 15) 290 262 27 (2 to 53)
1 253 252 1 (−14 to 16) 284 264 20 (7 to 33)
5 259 260 −1 (−20 to 18) 297 286 11 (−2 to 23)
10 230 281 −51 (−120 to 19) 277 271 5 (−9 to 20)
Days of sick leave/year†
−2 8.3 9.2 −0.9 (−3.9 to 2.1) 9.9 10.2 −0.3 (−3.0 to 2.3)
0 45.5 10.1 35.5 (29.7 to 41.2) 9.9 9.5 0.4 (−2.2 to 2.9)
1 24.5 9.4 15.1 (9.7 to 20.5) 9.7 9.3 0.4 (−2.3 to 3.0)
5 9.3 9.6 −0.3 (−3.5 to 3.0) 10.2 9.3 0.8 (−2.1 to 3.8)
10 3.8 8.2 −4.4 (−6.6 to −2.2) 6.6 7.5 −0.9 (−4.1 to 2.4)
Proportion on disability pension (%)*
−2 3.6 5.7 −2.2 (−3.6 to −0.8) 2.5 3.2 −0.7 (−1.4 to −0.1)
0 4.8 6.5 −1.7 (−3.3 to −0.1) 3.0 3.9 −1.0 (−1.7 to −0.2)
1 5.9 7.0 −1.1 (−2.9 to 0.7) 3.2 4.3 −1.0 (−1.8 to −0.2)
5 8.3 9.2 −0.9 (−3.2 to 1.3) 4.3 5.7 −1.4 (−2.4 to −0.3)
10 9.9 8.6 1.2 (−1.7 to 4.2) 4.8 7.0 −2.2 (−3.5 to −0.8)
Proportion married (%)‡
−2 72.0 68.9 3.1 (0.6 to 5.6) 68.3 65.8 2.5 (0.6 to 4.3)
0 73.1 70.2 2.9 (0.4 to 5.3) 70.7 67.5 3.3 (1.5 to 5.1)
1 74.0 70.6 3.4 (0.9 to 5.8) 71.0 68.2 2.7 (0.9 to 4.6)
5 77.0 72.2 4.8 (2.2 to 7.4) 72.6 69.8 2.8 (0.8 to 4.8)
10 79.7 73.1 6.5 (3.5 to 9.5) 73.2 70.6 2.6 (0.3 to 4.9)
Proportion divorced (%)‡
−2 9.6 10.9 −1.3 (−2.9 to 0.4) 6.9 8.4 −1.5 (−2.5 to −0.5)
0 9.9 11.4 −1.5 (−3.1 to 0.2) 7.8 9.6 −1.8 (−2.9 to −0.8)
1 10.1 11.6 −1.6 (−3.3 to 0.1) 8.6 10.1 −1.5 (−2.6 to −0.3)
5 9.8 12.0 −2.2 (−4.1 to −0.4) 9.9 12.3 −2.4 (−3.7 to −1.1)
10 9.8 13.1 −3.3 (−5.6 to −1.1) 13.1 14.9 −1.8 (−3.5 to 0.0)
Number of children*
−2 1.00 1.00 −0.01 (−0.16 to 0.15) 1.81 1.71 0.10 (0.03 to 0.18)
0 1.11 1.16 −0.05 (−0.20 to 0.10) 1.95 1.84 0.11 (0.03 to 0.19)
1 1.17 1.24 −0.07 (−0.22 to 0.08) 2.01 1.91 0.10 (0.02 to 0.18)
5 1.41 1.50 −0.10 (−0.27 to 0.08) 2.18 2.14 0.03 (−0.05 to 0.12)
10 1.72 1.72 0.00 (−0.19 to 0.19) 2.30 2.29 0.01 (−0.09 to 0.11)
Education
High grade (>8) in written mathematics in elementa-
ry school after diagnosis of LNB (%)§
52 45 6 (1 to 12) 43 42 2 (−3 to 6)
Cumulative incidence of high school completion 
before age 25 years (%)¶
45 38 7 (1 to 12) 42 37 5 (1 to 10)
*Includes only people aged 20-60 years at study inclusion.
†Includes only people aged 20-60 years at study inclusion and registered as employed.
‡Includes only people aged >20 years at study inclusion.
§Includes only siblings of LNB patients and population comparison cohorts.
¶Includes only people aged <17 years at study inclusion.
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Before study inclusion, income was higher 
among Lyme neuroborreliosis patients than among 
members of the general population cohort, but it 
decreased thereafter (table 3, supplementary figure 
E). In contrast, the income of family members of 
Lyme neuroborreliosis patients was higher than 
that of family members of people in the comparison 
cohort throughout the observation period 
(table 3, supplementary figure E). Among Lyme 
neuroborreliosis patients, the number of days of sick 
leave was substantially higher than for members of 
the comparison cohort during the year of diagnosis. 
However, two years after diagnosis, the number of 
days of sick leave did not differ substantially from 
that for members of the comparison cohort (table 3, 
supplementary figure E).
Compared with the population comparison 
cohort, the marriage rate was increased and the 
divorce rate decreased among Lyme neuroborreliosis 
patients, before as well as after study inclusion. We 
observed a similar trend among family members 
of patients (table  3, supplementary figure F). The 
number of children was almost identical for Lyme 
neuroborreliosis patients and members of the 
population comparison cohort, as well as for the two 
cohorts of family members (table 3, supplementary 
figure F). Children diagnosed as having Lyme 
neuroborreliosis had higher marks in written 
mathematics in elementary school, and more Lyme 
neuroborreliosis patients completed high school, 
compared with members of the comparison cohort 
(table 3, fig 4).
discussion
We did a population based nationwide cohort study 
of patients with Lyme neuroborreliosis among 
whom the diagnosis was established by a positive B 
burgdorferi intrathecal antibody test and a clinical 
diagnosis of Lyme borreliosis. Compared with 
members of a general population cohort, mortality 
was not increased among Lyme neuroborreliosis 
patients. However, Lyme neuroborreliosis patients 
had an increased risk of haematological and non-
melanoma skin cancers. Before their diagnosis, Lyme 
neuroborreliosis patients, as well as their family 
members, had higher incomes and employment rates 
and were less likely to receive disability pensions 
than people in the comparison cohort and their 
family members. However, after diagnosis of Lyme 
neuroborreliosis, income and employment rates 
decreased and risk of receipt of disability pensions 
increased slightly in the patient population but not 
in their family members, relative to people in the 
comparison cohorts.
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Fig 3 | Proportion of people aged 20-60 years at study 
inclusion registered as receiving disability pension. Top: 
Lyme neuroborreliosis (LNB) patients and members of 
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Strengths and limitations of study
Important design features of this study are its large size, 
population based nationwide design, and complete 
long term follow-up of the study cohorts. Access to 
national registries allowed identification of a well 
matched population based comparison cohort and 
cohorts of family members. These registries provided 
complete data on date of death, comorbidity, cancer 
diagnoses, educational status, income, and disability 
pension status.
We included only patients with a first time proven 
positive B burgdorferi intrathecal antibody test, 
which has a high diagnostic specificity for Lyme 
neuroborreliosis.16 Furthermore, the number of 
patients identified was in the same range as annual 
surveillance reports of Lyme neuroborreliosis.2 The 
registry based design precluded access to data on 
cerebrospinal fluid leucocyte counts and stage of Lyme 
neuroborreliosis, character of initial neurological 
symptoms, and antibiotic therapy. Therefore, we were 
unable to analyse the effect of clinical risk factors 
on long term prognosis. However, on the basis of the 
incidence reported in a previous Danish study, it is 
reasonable to assume that only a minority of patients 
had late disseminated (chronic or stage III) Lyme 
neuroborreliosis and that antibiotics were administered 
according to European treatment guidelines for this 
condition throughout the study period.3 19 By including 
only patients with a positive B burgdorferi intrathecal 
test, we are likely to have missed some patients with 
early Lyme neuroborreliosis.
Long term prognosis of patients with post-treatment 
Lyme disease syndrome has been intensively 
debated.5  6 12 20 We must emphasise that our study 
focuses on patients with Lyme neuroborreliosis and 
was not designed to evaluate the prevalence of post-
treatment Lyme disease syndrome.
Comparison with other studies
A key finding was the increased risk of haematological 
cancers up to 10 years after the Lyme neuroborreliosis 
diagnosis. A previous Danish-Swedish case-control 
study reported a threefold increased risk of mantle 
cell lymphoma in patients with a self reported history 
of Lyme borreliosis or presence of anti-B burgdorferi 
antibodies.21 In contrast, a large registry based Swedish 
study observed no increased risk of haematological 
malignancies among patients with serological 
evidence of borreliosis.22 We found that mortality after 
a diagnosis of haematological cancer did not differ 
substantially between Lyme neuroborreliosis patients 
and people in the population comparison cohort; that 
the increased risk of haematological cancers persisted 
even after exclusion of patients who were treated at a 
hospital department of haematology up to one year 
after study inclusion; and that Lyme neuroborreliosis 
patients had increased use of haematological outpatient 
facilities. This indicates that the increased risk of 
haematological cancers is unlikely to be explained 
by the presence of clinically manifest haematological 
diseases before Lyme neuroborreliosis or by 
misclassification of the haematological disease. Our 
data do not allow firm conclusions concerning a causal 
link between risk of haematological cancers and Lyme 
neuroborreliosis. Patients had a slightly increased risk 
of being diagnosed as having haematological cancers 
before their Lyme neuroborreliosis diagnosis (table 
1). Therefore, we may hypothesise that some Lyme 
neuroborreliosis patients harbour an unrecognised 
haematological malignancy or premalignant condition 
making them prone to second stage manifestations of 
Lyme borreliosis. In line with this hypothesis, invasive 
pneumococcal infection is associated with increased 
risk of a later diagnosis of myelomatosis.23 In addition, 
monoclonal B cell lymphocytosis increases the risk 
of infection and subsequent diagnosis of chronic 
lymphatic leukaemia.24 It remains possible that 
patients with an as yet unrecognised haematological 
cancer may have a higher risk of lumbar puncture and 
an intrathecal test for B burgdorferi antibodies leading 
to a higher rate of Lyme neuroborreliosis diagnosis in 
this patient group.
Outdoor activities increase exposure to both ticks 
and to ultraviolet light. This probably explains the 
finding of a 50% increased risk of non-melanoma skin 
cancers in Lyme neuroborreliosis patients.25
The increased risk of cerebral infarction during 
the first year after a Lyme neuroborreliosis episode 
is probably related to an increased frequency of 
neuroimaging procedures leading to detection of 
otherwise non-symptomatic cerebral infarctions. It 
is also consistent with reports of meningovascular 
involvement leading to lacunar infarctions secondary 
to obliteration of small penetrating arteries, primarily 
in patients with chronic Lyme neuroborreliosis.26
Lyme neuroborreliosis has been proposed to increase 
the risk of subsequent multiple sclerosis.27 However, 
we found no increased risk of this disease, consistent 
with a report on the geographical distribution of 
borreliosis and death due to multiple sclerosis in the 
United States.28
Increased morbidity is assumed to lead to increased 
use of hospital services. We observed a slightly 
increased use of outpatient hospital services in Lyme 
neuroborreliosis patients even several years after 
their diagnosis, without a corresponding increased 
use of these services by their family members. This 
seemed to be partly due to residual symptoms of Lyme 
neuroborreliosis, as patients showed excess use of 
outpatient facilities treating neurological conditions. 
A US study based on insurance claims data reported 
that a diagnosis of Lyme borreliosis was associated 
with higher total healthcare costs and 87% more 
outpatient visits over a 12 month period compared 
with controls.29
Lyme neuroborreliosis patients diagnosed in 
childhood and their siblings had higher educational 
achievement than members of the comparison cohort, 
indicating that Lyme neuroborreliosis in childhood 
does not affect cognition or learning ability and that 
the favourable educational outcome most likely stems 
from family related factors.
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Before the Lyme neuroborreliosis episode, patients 
and their family members had higher socioeconomic 
status compared with matched members of the 
general population cohort. However, after the Lyme 
neuroborreliosis diagnosis the employment rate 
and income among patients decreased to levels 
observed in the comparison cohort. At the same time, 
family members of Lyme neuroborreliosis patients 
maintained a higher level of income and employment 
than did family members of the comparison cohort. 
This indicates that Lyme neuroborreliosis decreases 
working capacity in a small fraction of patients, 
consistent with a Swedish study reporting a 12% rate 
of disabling sequelae five years after treatment for 
Lyme neuroborreliosis and with a Danish study that 
found a 5% rate of disability after a median 33 months 
of follow-up.39 Although living with a disabling chronic 
disease may increase the risk of divorce, we observed 
an increased marriage rate after the diagnosis of 
Lyme neuroborreliosis, compared with the general 
population cohort.30 31
Conclusion
We conclude that a proven diagnosis of Lyme 
neuroborreliosis does not have a substantial effect 
on long term survival, health, social functioning, 
or education. However, a diagnosis of Lyme 
neuroborreliosis is associated with increased risk of 
haematological and non-melanoma skin cancers and 
marginally decreased labour marked attachment.
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